Dune Medical wins Frost & Sullivan award

The company has developed a system that enables immediate detection of cancerous tissue during breast cancer surgery.

Medical device start-up Dune Medical Devices Ltd., which develops devices for the diagnosis of cancerous tissue during surgery, has been awarded the 2007 Frost & Sullivan European Technology Innovation of the Year Award for its interoperative breast cancer probe.

The device, which uses radio frequency-based spectroscopy, provides physicians carrying out surgery with the malignancy status of the patient's breast cancer margins in real-time.

Explaining the decision to give the award to Dune Medical, Frost & Sullivan wrote, "Following lumpectomy, cancer patients found to have positive (malignant) surgical margins typically require a second surgery, with added expense and trauma, to re-shave tumor sites for additional tissue removal. The Dune handheld probe holds significant promise to reduce re-excision procedures, improve patient outcomes and minimize surgical expenses."

Dune Medical was founded in 2002 by CEO Dr. Dan Hashimshony. The company's device recently received CE Mark certification and is currently undergoing further clinical trials for approval by the US Food and Drug Administration (FDA). Dune Medical held its last financing round a year ago, in which it raised $12.5 million from a group of investors led by Apax Partners.

Published by Globes [online], Israel business news - www.globes.co.il - on August 1, 2007

© Copyright of Globes Publisher Itonut (1983) Ltd. 2007

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018